Retatrutide is an investigational peptide that mimics three key gut hormones. Like semaglutide and tirzepatide, it activates GLP-1 receptors to regulate blood sugar and curb appetite. It also engages GIP receptors for enhanced insulin sensitivity and satiety, and glucagon receptors to further slow digestion and increase energy expenditure. This “GGG tri-agonist” profile gave study participants up to 24% average body-weight reduction over 48 weeks in Phase 2 trials.

Retatrutide is currently in Phase 3 clinical trials, with study completion expected in 2025. If safety and efficacy data meet FDA requirements—such as demonstrating at least a 5% average weight loss—approval could come in 2026. Until then, beware of any online offers claiming to sell retatrutide, as these are unregulated and potentially unsafe.